These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 17421115)

  • 1. What does it mean: appropriate therapy for methicillin-resistant Staphylococcus aureus?
    Viale P; Pea F
    Crit Care Med; 2007 Mar; 35(3):991; author reply 991-2. PubMed ID: 17421115
    [No Abstract]   [Full Text] [Related]  

  • 2. Optimal therapy for methicillin-resistant Staphylococcus aureus pneumonia: what is the best dosing regimen?
    Rello J; Mallol J
    Chest; 2006 Oct; 130(4):938-40. PubMed ID: 17035421
    [No Abstract]   [Full Text] [Related]  

  • 3. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices.
    Jeffres MN; Isakow W; Doherty JA; McKinnon PS; Ritchie DJ; Micek ST; Kollef MH
    Chest; 2006 Oct; 130(4):947-55. PubMed ID: 17035423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MRSA pneumonia: better outcome through continuous infusion of vancomycin?
    Blot S
    Crit Care Med; 2005 Sep; 33(9):2127-8. PubMed ID: 16148496
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
    Estes L; Orenstein R
    Clin Ther; 2007 Feb; 29(2):381-3; author reply 383-4. PubMed ID: 17472831
    [No Abstract]   [Full Text] [Related]  

  • 6. Vancomycin dosing for methicillin-resistant staphylococcus aureus nosocomial pneumonia.
    Hall RG; Adams-Huet B
    Chest; 2007 Sep; 132(3):1100-1; author reply 1102-3. PubMed ID: 17873214
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
    Estes L; Orenstem R
    Clin Ther; 2007 Apr; 29(4):759-60; author reply 760-1. PubMed ID: 17617300
    [No Abstract]   [Full Text] [Related]  

  • 8. [Effect of pharmacists' intervention on the antibiotic therapy for the methicillin-resistant Staphylococcus aureus (MRSA) infectious diseases in the intensive care unit].
    Imaura M; Kohata Y; Kobayashi K; Takahashi H; Yokoyama H; Akase T; Yamada Y
    Yakugaku Zasshi; 2011 Apr; 131(4):563-70. PubMed ID: 21467796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methicillin-resistant Staphylococcus aureus pneumonia treatment: do not confuse pharmacokinetics and pharmacodynamics.
    Moine P; Bédos JP
    Chest; 2007 Sep; 132(3):1101, author reply 1102-3. PubMed ID: 17873216
    [No Abstract]   [Full Text] [Related]  

  • 10. Appropriate pharmacokinetic index for outcome in Staphylococcus aureus pneumonia.
    Potoski BA; Paterson DL
    Chest; 2007 Sep; 132(3):1101-2; author reply 1102-3. PubMed ID: 17873215
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
    Lyles A
    Clin Ther; 2007 Feb; 29(2):384. PubMed ID: 17472833
    [No Abstract]   [Full Text] [Related]  

  • 12. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia.
    Jeffres MN; Isakow W; Doherty JA; Micek ST; Kollef MH
    Clin Ther; 2007 Jun; 29(6):1107-15. PubMed ID: 17692725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of enteral vancomycin for the control of methicillin-resistant Staphylococcus aureus in intensive care units.
    Humphreys H; Smyth EG
    J Hosp Infect; 2005 Mar; 59(3):259-61; author reply 263-6. PubMed ID: 15694985
    [No Abstract]   [Full Text] [Related]  

  • 14. Optimal dose of vancomycin for treating methicillin-resistant Staphylococcus aureus pneumonia in critically ill patients.
    Chung J; Oh JM; Cho EM; Jang HJ; Hong SB; Lim CM; Koh YS
    Anaesth Intensive Care; 2011 Nov; 39(6):1030-7. PubMed ID: 22165354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Linezolid versus vancomycin cost in the treatment of staphylococcal pneumonia.
    Huon JF; Boutoille D; Caillon J; Orain J; Crochette N; Potel G; Abgueguen P; Moal F; Navas D
    Med Mal Infect; 2020 May; 50(3):252-256. PubMed ID: 31387813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential impact of vancomycin pulmonary distribution on treatment outcomes in patients with methicillin-resistant Staphylococcus aureus pneumonia.
    Scheetz MH; Wunderink RG; Postelnick MJ; Noskin GA
    Pharmacotherapy; 2006 Apr; 26(4):539-50. PubMed ID: 16553514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacologic treatment options for nosocomial pneumonia involving methicillin-resistant Staphylococcus aureus.
    Maclayton DO; Hall RG
    Ann Pharmacother; 2007 Feb; 41(2):235-44. PubMed ID: 17299012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacotherapy for methicillin-resistant Staphylococcus aureus nosocomial pneumonia.
    Segarra-Newnham M; Church TJ
    Ann Pharmacother; 2012 Dec; 46(12):1678-87. PubMed ID: 23232021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addition of rifampin to vancomycin for the treatment of pneumonias due to methicillin-resistant Staphylococcus aureus: caveat emptor.
    Ramsey KM; Mazer MA
    Crit Care Med; 2010 Jan; 38(1):326-7. PubMed ID: 20023486
    [No Abstract]   [Full Text] [Related]  

  • 20. A holistic approach to MRSA eradication in critically ill patients with MRSA pneumonia.
    Wenisch C; Laferl H; Szell M; Smolle KH; Grisold A; Bertha G; Krause R
    Infection; 2006 Jun; 34(3):148-54. PubMed ID: 16804658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.